AnaptysBio Inc (NASDAQ:ANAB)’s share price fell 10.7% during trading on Friday . The stock traded as low as $68.04 and last traded at $72.33. 836,519 shares changed hands during trading, an increase of 126% from the average session volume of 369,494 shares. The stock had previously closed at $81.04.
Several brokerages have commented on ANAB. Zacks Investment Research downgraded AnaptysBio from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $140.00 price target on AnaptysBio and gave the company a “buy” rating in a report on Friday. Credit Suisse Group set a $143.00 price target on AnaptysBio and gave the company a “buy” rating in a report on Friday. Royal Bank of Canada reiterated a “hold” rating and set a $84.00 price target on shares of AnaptysBio in a report on Wednesday, August 8th. Finally, JMP Securities lowered their price target on AnaptysBio from $180.00 to $153.00 and set a “buy” rating on the stock in a report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. AnaptysBio presently has an average rating of “Buy” and a consensus target price of $130.50.
The company has a debt-to-equity ratio of 0.01, a current ratio of 16.19 and a quick ratio of 16.19. The firm has a market cap of $1.93 billion, a P/E ratio of -47.59 and a beta of 3.47.
Hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its position in shares of AnaptysBio by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,342 shares of the biotechnology company’s stock valued at $5,992,000 after acquiring an additional 5,067 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of AnaptysBio in the second quarter valued at approximately $211,000. Brown Advisory Inc. boosted its position in shares of AnaptysBio by 1.5% in the second quarter. Brown Advisory Inc. now owns 102,114 shares of the biotechnology company’s stock valued at $7,253,000 after acquiring an additional 1,500 shares during the period. BlackRock Inc. boosted its position in shares of AnaptysBio by 2.9% in the second quarter. BlackRock Inc. now owns 1,464,624 shares of the biotechnology company’s stock valued at $104,046,000 after acquiring an additional 41,507 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of AnaptysBio in the second quarter valued at approximately $780,000.
About AnaptysBio (NASDAQ:ANAB)
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Story: Google Finance Portfolio
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.